The study of gemcitabine, GM-CSF and low-dose IL-2 combination for treatment of colon cancer patients showed that this regimen had strong immunologic and antitumor activity associated with immunologic events that strongly resembled those induced by cancer vaccine therapy [20]. The gene discussed is CSF2; the disease is malignant colon neoplasm.